Earnings Call Intelligence Subscribe
Home › Call Sheets › BIIB › Q3'26
Call sheet · Q3'26

Biogen (BIIB)

Q3'26 earnings call · held October 28, 2026 · compared with the Q2'26 call · management-credibility review
9/12
Disclosure score
1 high, 4 medium, 4 low flags
Financial quality
Bottom line
The sleeper story here isn't the 11% revenue beat, it's that three separate growth products simultaneously borrowed from Q4 to make Q3 look stronger, something management disclosed itself via the SkyClarus and Sifovri inventory builds and the Spinraza conversion pull-forward, buried under an otherwise triumphant tone. The obvious headline, return to growth and raised guidance, is real, but the guidance raise only moved the floor from $12.00 to $12.20 while leaving the $13.00 ceiling untouched. The binding constraint isn't demand, it's credibility heading into the binary SLE catalyst: Priya Singhal went from saying she remained confident in the SLE trial's design and probability of success to flatly declining to discuss confidence just weeks before the December readout, and two previously-touted pipeline assets, BIB91 and dearnersen, vanished from the conversation entirely. My view changes if Q4 Spinraza, SkyClarus, and Sifovri revenue actually reverses cleanly as guided without further adjustments, and if management re-engages on BIB91/dearnersen status next quarter rather than letting them quietly fade.

The 30-second version

  • Three growth products are quietly borrowing from Q4 to flatter Q3
  • Headline: 11% revenue growth and raised guidance; Reality: the raise only moved the floor
  • Priya Singhal went silent on SLE confidence right before the binary readout, and two pipeline assets vanished entirely

What changed this quarter

MetricQ2'26Q3'26Change
Total Revenue$2.7B, +3% YoY$2.8B, +11% YoYAcceleration, largely Appellus-driven
Core Pharma Revenue$1.8B, +4% YoY/+12% QoQ$2.0B, +18% YoY/+9% QoQQoQ deceleration despite YoY beat
Biogen Standalone Growth Portfolio$933M, +9% YoY/+10% QoQ, ex-Appellus$1.26B, +50% YoY, ex-AppellusAccelerating even before Appellus contribution
Core OpEx growth YoY+20%+27%Opex growing faster than revenue
Free Cash Flow$408M$600M+47% QoQ
Net Debt$6.8B$6.4BDeleveraging on track
Sifovri + Empaveli Revenue$128M (partial quarter)$243M (full quarter)First full quarter, ~$1B run rate
Spinraza Revenue$402M, +2%/+7%$461M, +23%/+15%Inflated by one-time HD transition doses, flagged by mgmt
Vumerity Revenue$197M, -7% YoY$192M, -11% YoYDecline accelerating on Part D formulary pressure
Lekembe In-Market Revenue$184M, +15%/+9%$202M, +67%/+10%YoY growth tripled, strongest in portfolio

Accountability tracked

7 new promises made6 narrative shifts flagged8 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full BIIB Q3'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.